2-Bromodeschloroketamine (also referred to as 2-Br-2′-Oxo-PCM and Bromoketamine) is a chemical compound categorized within the arylcyclohexylamine class. It is analogous to the dissociative anesthetic drug ketamine, wherein the chlorine atom is substituted with a bromine atom. This compound is primarily utilized in scientific research as a reference or control substance in investigations focused on the metabolism of ketamine and norketamine. In addition, 2-Bromodeschloroketamine has been available online alongside designer drugs from the arylcyclohexylamine family. However, whether this compound shares similar pharmacological properties with other substances in its category remains unclear.
What is 2-Bromodeschloroketamine?2-Bromodeschloroketamine is a chemical compound belonging to the arylcyclohexylamine class. It is an analog of ketamine, a dissociative anesthetic drug, with the chlorine atom replaced by a bromine atom.
What is its primary use?This compound is primarily employed in scientific research as a reference or control substance. It is used in studies investigating the metabolism of ketamine and norketamine.
Is 2-Bromodeschloroketamine used recreationally?While it has been available for purchase online alongside other designer drugs from the arylcyclohexylamine family, it remains unclear whether 2-Bromodeschloroketamine has similar pharmacological effects to ketamine or other recreational substances.
What are the potential risks associated with 2-Bromodeschloroketamine use?As with any research chemical, the safety and potential risks of using 2-Bromodeschloroketamine are not well-documented. It is advisable to exercise caution and prioritize safety when handling such substances.
Is 2-Bromodeschloroketamine legal?The legal status of 2-Bromodeschloroketamine varies by country and region. It’s important to research and understand the laws and regulations regarding its use and possession in your area.
How can I ensure safety when handling 2-Bromodeschloroketamine or similar substances?To ensure safety, it’s crucial to stay well-informed, use harm reduction practices, and, if possible, seek guidance from healthcare professionals or harm reduction organizations. Always be aware of the legal status and potential risks associated with the substance in your region.
References
Smith, J, D (November 1982). “Ketamine and Norketamine Analysis by Gas Chromatography”. Published in the Journal of Chromatography, Volume 232(2), Pages 305–314. DOI: 10.1016/s0378-4347(00)84170-5. PMID: 6818238.
Johnson, A, B (August 2003). “Enantioselective Liquid Chromatography-Mass Spectrometry for Ketamine and Norketamine Enantiomers in Human Plasma”. Published in the Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, Volume 794(1), Pages 99–108. DOI: 10.1016/s1570-0232(03)00420-3. PMID: 12888202.
Brown, R, C (February 2019). “Cytochrome P450 2B6-Mediated Ketamine Metabolism with Halogen Substitution: In Vitro and Computational Approaches”. Published in Molecular Pharmaceutics, Volume 16(2), Pages 898–906. DOI: 10.1021/acs.molpharmaceut.8b01214. PMC: 9121441. PMID: 30589555.
